Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Aegleio

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

North East and North Cumbria NHS rolls out digital health platform to combat chronic kidney disease, affecting 1 in 10 UK adults

In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, providing...

Healthinote (by Cognitant)

- PMLiVE

Bridging the gap in personalised digital support: My Stroke Companion

To empower stroke survivors to engage with their care, Cognitant, in partnership with University College London Hospitals (UCLH), identified a need for a new digital health companion that can support...

Healthinote (by Cognitant)

- PMLiVE

Kidney Research UK invests in Healthinote patient education platform which could support >15m people with long term health conditions

Kidney Research UK, the leading charity dedicated to kidney health, has made a significant investment in Cognitant Group Ltd, a leading provider of digital education and support tools to improve...

Healthinote (by Cognitant)

- PMLiVE

Health literacy & the creation of shared decision aids for patients with cancer

In this blog, Gini Melesi, Head of Transformation, East of England Cancer Alliance, & Diane Whitney, Head of Brachytherapy Physics, Cambridge University Hospitals NHS Foundation Trust, explore the relationship between...

Healthinote (by Cognitant)

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

- PMLiVE

From Noise to Impact: Why Simplicity Is The Health Communicator’s Most Powerful Tool

Clear health communication has never been more critical, as shown by the 2025 surge in ADHD self-diagnoses in the UK, driven by misleading social media content. In a noisy, fast-paced...

Fox&Cat

- PMLiVE

Eli Lilly announces $3bn expansion to US injectables manufacturing facility

The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

- PMLiVE

Sanofi unveils plans to build €1bn insulin production base in China

The site will focus on serving the insulin medication needs of local diabetic patients

- PMLiVE

Common antidiabetic drug metformin found to slow growth of precancerous cells

The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

- PMLiVE

Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

It is hoped that a once-weekly treatment option could improve adherence rates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links